{"data":[{"accessionNo":"0001831942-26-000032","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":null,"reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4244590,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000032","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":null,"reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":4244590,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000032","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":null,"reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":4244590,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000032","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":null,"reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":4244590,"percentOfClass":9.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-352371","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":2960404,"percentOfClass":6.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-352371","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":2220303,"percentOfClass":5.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-352371","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2220303,"percentOfClass":5.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-352371","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover Fund I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":740101,"percentOfClass":1.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-352371","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"TCG Crossover GP I, LLC","reportingCik":null,"personType":"OO","sharesOwned":740101,"percentOfClass":1.8,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000947871-26-000804","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000947871-26-000804","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-30","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-226886","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":4100029,"percentOfClass":9.99,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-226886","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3075022,"percentOfClass":7.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-226886","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":3075022,"percentOfClass":7.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-226886","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover Fund I, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1025007,"percentOfClass":2.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001193125-26-226886","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":"92840H400","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"TCG Crossover GP I, LLC","reportingCik":null,"personType":"OO","sharesOwned":1025007,"percentOfClass":2.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4383508,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":4383508,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":4383508,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001831942-26-000008","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":4383508,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001172661-26-001115","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Dr. Jeffrey R. Jay, M.D.","reportingCik":null,"personType":"HC,IN","sharesOwned":2055834,"percentOfClass":4.95,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001172661-26-001115","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Ms. Lillian Nordahl","reportingCik":null,"personType":"HC,IN","sharesOwned":2055834,"percentOfClass":4.95,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001172661-26-001115","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-12-31","reportingPerson":"Great Point Partners, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":2055834,"percentOfClass":4.95,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000947871-26-000193","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":null,"personType":"IA","sharesOwned":1639700,"percentOfClass":4.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000947871-26-000193","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":null,"personType":"IA","sharesOwned":1420300,"percentOfClass":3.6,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-26-015994","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"StemPoint Capital LP","reportingCik":null,"personType":"IA","sharesOwned":616749,"percentOfClass":1.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-26-015994","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"StemPoint Capital Management GP LLC","reportingCik":null,"personType":"OO","sharesOwned":616749,"percentOfClass":1.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-26-015994","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Michelle Ross","reportingCik":null,"personType":"HC,IN","sharesOwned":616749,"percentOfClass":1.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001274173-26-000068","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-26-015351","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":1953045,"percentOfClass":4.71,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-26-015351","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":1953045,"percentOfClass":4.71,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-26-015351","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":1953045,"percentOfClass":4.71,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000102909-26-000313","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics Inc","ticker":"VTGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":1824738,"percentOfClass":4.62,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-25-112649","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Wilmot B. Harkey","reportingCik":null,"personType":"HC","sharesOwned":3185564,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-25-112649","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Nantahala Capital Management, LLC","reportingCik":null,"personType":"IA","sharesOwned":3185564,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001104659-25-112649","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001411685","issuerName":"VISTAGEN THERAPEUTICS, INC.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"Daniel Mack","reportingCik":null,"personType":"HC","sharesOwned":3185564,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001814554-25-000180","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Ms. Lillian Nordahl","reportingCik":null,"personType":"HC,IN","sharesOwned":2055834,"percentOfClass":6.28,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001814554-25-000180","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Great Point Partners, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":2055834,"percentOfClass":6.28,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0001814554-25-000180","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Dr. Jeffrey R. Jay, M.D.","reportingCik":null,"personType":"HC,IN","sharesOwned":2055834,"percentOfClass":6.28,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000947871-25-001019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":null,"personType":"IA","sharesOwned":1639700,"percentOfClass":5.34,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000947871-25-001019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics, Inc.","ticker":"VTGN","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-09-30","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":null,"personType":"IA","sharesOwned":1420300,"percentOfClass":4.63,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"},{"accessionNo":"0000102909-25-000334","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001411685","issuerName":"Vistagen Therapeutics Inc","ticker":"VTGN","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":1687735,"percentOfClass":5.5,"filedAt":"2025-10-31","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn"}],"updatedAt":"2026-11-05T14:30:09.423Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/vtgn","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}